Group 1 - ST HuLuWa and its chairman Liu Jingping are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1] - The company claims that its production and operational activities are currently normal and orderly [1] Group 2 - BaiLi TianHeng plans to apply for the registration and issuance of debt financing instruments to optimize its debt structure, with a proposed issuance scale not exceeding 10 billion RMB [2] - The company asserts that this initiative will promote high-quality, stable, and sustainable development, benefiting all shareholders without harming minority shareholders [2] Group 3 - PaiLin Bio's controlling shareholder has signed a supplementary agreement for share transfer, extending the final deadline for the transaction to June 30, 2026, due to ongoing state-owned enterprise and antitrust reviews [3] - The share transfer is subject to compliance confirmation from the Shenzhen Stock Exchange and other regulatory approvals [3] Group 4 - JinCheng Pharmaceutical's subsidiary is required to pay approximately 21.6 million RMB in back taxes and penalties for the years 2017 and 2018, which have now been settled [4] - The company plans to seek compensation from previous equity transfer parties, with a potential impact of approximately -9.93 million RMB on the net profit attributable to shareholders for the current period [4] Group 5 - HengRui Pharmaceutical has signed an exclusive licensing agreement with HanSen Pharmaceutical for the SHR6508 project, allowing HanSen to commercialize the product [5] - This agreement enables HengRui to focus resources on priority treatment areas and leverage commercial services to expedite market entry [5]

Market Updates - The total profit of industrial enterprises above designated size in China reached 66,268.6 billion yuan from January to November, showing a year-on-year growth of 0.1%. New momentum industries, represented by equipment manufacturing and high-tech manufacturing, maintained rapid growth [2] - The National Financial Work Conference emphasized the continuation of a more proactive fiscal policy in 2026, aiming to boost consumption and implement special actions to stimulate consumption [2] - The National Industrial and Information Technology Work Conference outlined key tasks for 2026, focusing on stabilizing growth, enhancing innovation, promoting integration, optimizing governance, and preventing risks [2] - The People's Bank of China and the State Administration of Foreign Exchange announced the nationwide promotion of integrated currency pools for multinational companies, facilitating the collection and use of funds [2] - The Beijing Stock Exchange issued guidelines to regulate various types of related party transactions and significant trading behaviors [2] Industry Insights - The Shanghai Stock Exchange expanded the fifth set of listing standards to commercial rocket enterprises, aiming to accelerate the development of commercial aerospace and support national strategies [6] - The digital financial high-quality development implementation plan was released, proposing 33 tasks to enhance digital finance governance, services, technology application, and risk management [7] - The establishment of the humanoid robot and embodied intelligence standardization committee aims to promote the maturation and application of humanoid robot technologies [9] Company News - China Duty Free Group won a bid for the duty-free project at Beijing Capital International Airport, with a guaranteed operating fee of 480 million yuan for the first year and a sales commission of 5% [11] - Wangfujing also secured a bid for another section of the airport's duty-free project, with a guaranteed operating fee of 113 million yuan for the first year [11] - China Aluminum International signed a contract worth approximately 14 billion yuan with an overseas client, which is expected to positively impact the company's revenue [12] - XCMG Group plans to increase its shareholding in XCMG Machinery by investing between 80 million and 160 million yuan within six months [12] - China Shenhua's subsidiary successfully completed the commercial operation of its second phase expansion project, enhancing its power generation capacity [12] - Heng Rui Medicine signed an exclusive licensing agreement with Hansoh Pharmaceutical for the SHR6508 project, with potential milestone payments totaling up to 1.9 billion yuan [13]

Market News - The Ministry of Finance announced that a more proactive fiscal policy will continue in 2026, focusing on expanding fiscal expenditure, optimizing government bond tools, enhancing transfer payment efficiency, and improving expenditure structure [3] - The National Bureau of Statistics will release the December PMI data on December 31, with November's manufacturing PMI at 49.2%, a slight increase of 0.2 percentage points from October [4] - The People's Bank of China aims to significantly increase the scale and proportion of various long-term funds invested in A-shares, promoting a virtuous cycle between capital market stability and high-quality economic development [6] - The Shanghai and Shenzhen Stock Exchanges announced a series of fee reduction measures for 2026, expected to save over 1.9 billion yuan in total [7] Sector Developments - The Ministry of Industry and Information Technology established a standardization committee for humanoid robots and embodied intelligence, focusing on key technologies and industry standards [11] - The 2025 Shenzhen Brain Conference aims to create a platform for industry integration and innovation [13] - The 2025 China Green Hydrogen Industry Conference will discuss policies and technological breakthroughs that will impact the green hydrogen industry chain [14] Individual Stock Events - CATL plans to apply sodium batteries on a large scale in various sectors including battery swapping and energy storage in 2026 [17] - Xiaomi's co-founder plans to reduce holdings of up to $2 billion in B-class common stock [17] - ST Huluwawa and its chairman are under investigation for information disclosure violations [17] Lock-up Expiration - A total of 34 companies will have lock-up shares released this week, amounting to 3.697 billion shares with a total market value of approximately 58.895 billion yuan [18] - The peak lock-up expiration date is December 30, with 13 companies releasing shares worth a total of 27.645 billion yuan [18] Institutional Outlook - CITIC Securities highlights that 39 out of 360 industry/theme ETFs reached new highs in December, with a focus on communication and resource-related ETFs [25] - Guojin Securities identifies new investment themes emerging in 2026, emphasizing the importance of AI investments and the recovery of global manufacturing [26] - Zhongtai Securities believes there is still upward potential in the market before the Spring Festival, with opportunities for low-cost positioning [27]

Core Viewpoint - The article discusses various companies' recent announcements regarding stock price fluctuations, operational updates, and strategic partnerships, highlighting potential investment opportunities and risks in the market. Group 1: Company Announcements - Aerospace Development reported a revenue of 1.697 billion yuan for the first three quarters of 2025, with a significant increase attributed to ship deliveries, while its subsidiary's revenue contribution remains below 1% [3] - Victory Energy announced that it may apply for a trading suspension if its stock price continues to rise, indicating potential risks for investors [4] - Jia Mei Packaging also warned of possible trading suspension due to significant stock price deviations from its fundamentals, urging investors to be cautious [5][6] - Fenglong Co. stated that its acquirer, UBTECH, has no plans to change its main business or conduct significant asset transactions in the next 12 months [7] - ST Huluwa is under investigation by the China Securities Regulatory Commission for information disclosure violations, but its operations continue normally [8] Group 2: Project Updates - Yijing Optoelectronics announced delays in its photovoltaic project in Anhui due to industry-wide capacity mismatches, leading to a halt in production and potential financial liabilities [9] - Tongyu Communication cautioned about the risks of irrational market speculation following a significant stock price increase [10] - Junda Co. clarified that its strategic cooperation with Shangyi Optoelectronics will not have a major impact on its current financial performance due to the preliminary nature of the agreement [12] Group 3: Strategic Partnerships and Acquisitions - Hengrui Medicine signed an exclusive licensing agreement with Hansoh Pharmaceutical, which includes a 30 million yuan upfront payment and potential milestone payments totaling up to 190 million yuan [13] - Tongye Technology plans to acquire a 91.69% stake in Beijing Silingke Semiconductor Technology for 561 million yuan, focusing on power IoT communication chips [14] - ST Lutong intends to apply for the removal of risk warnings after a shareholder's commitment to repay funds misappropriated by the actual controller [15] Group 4: New Contracts and Market Expansion - Wangfujing won a bid for the Beijing Capital International Airport duty-free project, with a guaranteed operating fee of 113 million yuan for the first year and a sales commission of 5%, marking its entry into a major international hub [17]

Group 1 - Aerospace Development's subsidiary, Chongqing Tianmu Satellite Technology Co., Ltd., accounted for less than 1% of the company's total revenue in the first three quarters of 2025 [2] - Aerospace Development achieved a revenue of 1.697 billion yuan in the first three quarters of 2025, an increase attributed to ship deliveries [2] - The company focuses on aerospace defense information technology, continuing to develop blue army systems and new-generation communication and command equipment [2] Group 2 - Victory Energy announced that if its stock price continues to rise, it may apply for a trading suspension for verification [3] - Jia Mei Packaging stated that its stock price has significantly deviated from its fundamentals, and it may also apply for a trading suspension if prices rise further [4] - Fenglong Co. confirmed that there are no plans to change its main business or make significant adjustments in the next 12 months [5] Group 3 - ST Huluwa announced that the company and its chairman are under investigation by the China Securities Regulatory Commission for information disclosure violations [6] - Yijing Optoelectronics is facing challenges in its photovoltaic project in Quanjiao County, with a potential investment agreement termination and a demand for repayment of 140 million yuan [7] - Tongyu Communications warned of risks related to market sentiment and irrational speculation due to significant stock price fluctuations [8] Group 4 - Junda Co. stated that its strategic cooperation agreement with Shangyi Optoelectronics will not have a significant impact on its current operating performance [9] - Heng Rui Pharmaceutical signed an exclusive licensing agreement with Hansoh Pharmaceutical, with potential milestone payments totaling up to 190 million yuan [10] - Tongye Technology plans to acquire 91.69% of Beijing Silingke Semiconductor Technology Co., Ltd. for 561 million yuan [11] Group 5 - ST Lutong intends to apply for the removal of other risk warnings after a shareholder repaid 10.2254 million yuan in funds [12] - Wangfujing won the bid for the Beijing Capital International Airport duty-free project, with a guaranteed operating fee of 113 million yuan for the first year [14]

Major Events - Fenglong Co., Ltd. announced that after the change of control, the company will continue to focus on its original business, with no plans for significant adjustments or asset restructuring in the next 12 months [1] - The company aims to optimize management and resource allocation to enhance operational and profitability capabilities, although uncertainties remain regarding future business cooperation [1] Financial Transactions - Tongyi Technology plans to pay 561 million yuan to acquire 91.69% of Beijing Silin Technology Co., Ltd. through a cash transaction [9] - Hengrui Medicine signed an exclusive licensing agreement with Hansoh Pharmaceutical for the SHR6508 project, which includes an upfront payment of 30 million yuan and potential milestone payments up to 190 million yuan [2] Operational Updates - Yijing Optoelectronics received a hearing notice from the Quanjiao Economic Development Zone regarding potential administrative decisions due to failure to fulfill prior agreements related to a solar project [3] - China Shenhua's subsidiary successfully completed a 168-hour trial run of its new power generation unit, which will enhance regional power supply stability [5][6] Strategic Developments - Kingfisher Co., Ltd. won a bid for the duty-free project at Beijing Capital International Airport, which could enhance its market presence, although the project is still subject to contract finalization [10] - Jun Da Co., Ltd. stated that its strategic cooperation with Shangyi Optoelectronics will not significantly impact current operating performance due to the preliminary nature of the agreement [4] Revenue Insights - Aerospace Development reported a revenue of 1.697 billion yuan for the first three quarters of 2025, with a significant contribution from ship deliveries, while its satellite operations accounted for less than 1% of total revenue [7]

由于个人工作安排，黄浣琪女士已辞任公司联席公司秘书一职，并不再担任上市规则第3.05条项下的公 司授权代表，以及上市规则第19.05(2)条及公司条例(香港法例第622章)第16部项下所规定代表公司于香 港接收法律程序文件及通知的公司授权代表(法律程序文件代理人)，自2025年12月26日起生效。 翰森制药(03692)发布公告，严嘉先生获委任为独立非执行董事，其同时获委任为公司审核委员会成员 及环境、社会及管治委员会成员，自2025年12月26日起生效。 李亮贤先生已获委任为联席公司秘书，李亮贤先生亦已获委任为授权代表及法律程序文件代理人，自 2025年12月26日起生效。 ...

由于个人工作安排，黄浣琪女士已辞任公司联席公司秘书一职，并不再担任上市规则第3.05条项下的公 司授权代表，以及上市规则第19.05(2)条及公司条例(香港法例第622章)第16部项下所规定代表公司于香 港接收法律程序文件及通知的公司授权代表(法律程序文件代理人)，自2025年12月26日起生效。 智通财经APP讯，翰森制药(03692)发布公告，严嘉先生获委任为独立非执行董事，其同时获委任为公司 审核委员会成员及环境、社会及管治委员会成员，自2025年12月26日起生效。 李亮贤先生已获委任为联席公司秘书，李亮贤先生亦已获委任为授权代表及法律程序文件代理人，自 2025年12月26日起生效。 ...

Core Viewpoint - Hansoh Pharmaceutical (3692.HK) has entered into a licensing agreement to obtain exclusive rights for the development, production, and commercialization of the innovative drug SHR6508 in China (excluding Hong Kong, Macau, and Taiwan) [1] Group 1: Product Development - SHR6508 is a calcium-sensing receptor (CaSR) allosteric modulator currently in Phase III clinical trials, intended for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) requiring dialysis [1] - This collaboration signifies Hansoh Pharmaceutical's further deepening of its product portfolio in the nephrology sector, enhancing its core competitiveness [1] Group 2: Market Position - Hansoh Pharmaceutical has already launched an innovative nephrology drug, Shengluo Lai® (Pemosaject), in 2023, which is used for treating renal anemia [1] - The company possesses a mature commercialization system and market access capabilities in the fields of nephrology and dialysis [1]

Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3692） 董事名單與其角色和職能 翰森製藥集團有限公司（「本公司」）董事（「董事」）會（「董事會」）成員如下： 執行董事 鍾慧娟女士 （主席兼首席執行官） 孫遠女士 呂愛鋒博士 獨立非執行董事 林國強先生 陳尚偉先生 楊東濤女士 嚴嘉先生 董事會已成立五個委員會，並制定有關職權範圍。該等委員會的成員資料載列如 下 ： | 委員會 | | | 戰略 | 環境、社 | | | --- | --- | --- | --- | --- | --- | | | 審核 | 薪酬 | 及發展 | 會及管治 | 提名 | | 董事 | 委員會 | 委員會 | 委員會 | 委員會 | 委員會 | | 鍾慧娟女士 | | 成員 | 主席 | | 主席 | | 孫遠女士 | | | | | | | 呂愛鋒博士 | | | 成員 | 主席 | | | 林國強先生 | 成員 | 成員 | | | 成員 | | 陳尚偉先生 | 主席 | | 成員 | 成員 | 成員 | | 楊東濤 ...